drugset / Trial / NCT00157040

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

NCT00157040

Phase 2/3 Completed 50 enrolled Baxalta now part of Shire
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study is a pharmacokinetic evaluation, and Part 2 is an evaluation of efficacy and safety.

Timeline

Start
2002-06-07
Primary completion
2005-01-04
Completion
2005-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ADVATE Protein / enzyme biologic

Indications